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Movement Disorder Phenotypes in
Children With 22q11.2 Deletion
Syndrome
The 22q11.2 deletion syndrome (22q11.2DS) is associated
with a broad spectrum of clinical phenotypes, including con-
genital heart defects and immune deficiencies. In addition,
there is also an increased risk of psychiatric disorders, cogni-
tive deficits, and functional motor impairments.1-3 To date, a
systematic examination of movement disorders has not been
undertaken in this group.
Nineteen participants with 22q11.2DS (11 male: 8 female;
median age, 12.7 years; range, 6.8–17.1 years), and 13 sibling
controls (7 male: 6 female; median age, 11.2 years; range, 7.5–
17.5 years) were recruited following informed consent, via
ongoing cohort studies at Cardiff University (CU) with no fur-
ther selection criteria applied. Ethical approval was provided
by CU School of Medicine Research Ethics (reference: 17/69).
The presence of the 3-Mb 22q11.2 deletion was confirmed
using the Infinium PsychArray-v1.1 (Illumina) platform, fluo-
rescence in situ hybridization or genetic arrays through the
National Health Service medical genetics departments.
Data collected included sex, age at examination, medical com-
orbidities, and developmental history alongside assessment of
full-scale intelligence quotient (IQ), psychiatric symptoms, and
coordination performance. Motor assessment involved a stan-
dardized videotaped clinical examination using a modified Burke-
Fahn-Marsden Dystonia (BFMDRS) rating scale protocol.4
Examinations were reviewed independently by 3 neurologists
blinded to all clinical information. Reviewers indicated if a move-
ment disorder was observed and determined its phenomenology
and body distribution. A movement disorder was considered pre-
sent when there was agreement between all neurologists. Statisti-
cal analysis was carried out in R, using Fisher’s exact tests, chi-
squared tests, Pearson’s correlations, and t tests as appropriate.
Sample demographics are presented in Table 1. There was a
higher rate of movement disorders in the 22q11.2DS group
compared with controls (P = 0.0002), with consensus agree-
ment for a movement disorder in 18 of 19 children with
22q11.2DS (94.7%) compared with 4 of 13 of controls
(30.8%). Dystonia was the most common movement disorder
subtype, in isolation (94.4%, n = 17) and combined with upper
limb distal jerks (5.6%, n = 1). The limbs and craniocervical
region were most commonly affected, with upper limb involve-
ment in all 18 cases (Videos 1–3). Three of 4 controls displayed
isolated dystonia, with upper limb involvement in all 4. In the
22q11.2DS cohort, dystonia severity was mild (mean BFMDRS,
24.93/120) but was associated with lower IQ (r = −0.52,
P = 0.03) and higher anxiety symptoms (r = 0.57, P = 0.03).
This is the first cohort study investigating the prevalence
and type of movement disorders in young people with
22q11.2DS. Dystonia was the most commonly observed sub-
type, although these features were mild and tended to be asso-
ciated with action. Identification of true movement disorders is
often challenging in this age range, but the frequency of dys-
tonic signs in the 22q11.2DS group indicate that they were
associated with the 22q11.2DS phenotype, rather than
neuromotor immaturity. More severe dystonia was associated
with lower IQ and higher levels of anxiety. The 22q11.2
deletion is known to affect brain development,5,6 and genes in
the region such as COMT are expressed in the brain.7 Our
study is a cross-sectional, longitudinal examination throughout
childhood, adolescence, and into adult-life and is required to
gain a more comprehensive understanding of the 22q11.2DS
motor phenotype. Although this cohort is relatively small, the
high rate and preponderance of dystonia indicate that it is likely
part of the neurodevelopmental phenotype of 22q11.2DS.
Author Contributions
Adam C Cunningham had a major role in the acquisition of
data; interpreted the data; and drafted the article for intellec-
tual content. Wilson Fung had a major role in the acquisition
of data and revised the article for intellectual content. Thomas
H. Massey had a major role in the acquisition of data and
revised the article for intellectual content. Jeremy Hall inter-
preted the data and revised the article for intellectual content.
Michael J. Owen interpreted the data and revised the article
for intellectual content. Marianne B. M. van den Bree designed
and conceptualized the study, interpreted the data, and revised
the article for intellectual content. Kathryn J. Peall designed
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
© 2020 The Authors. Movement Disorders published by Wiley Periodi-
cals, Inc. on behalf of International Parkinson and Movement Disorder
Society.
This is an open access article under the terms of the Creative
Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly
cited.
*Correspondence to: Dr. Kathryn Peall, Neuroscience and Mental
Health Research Institute, Cardiff University, Hadyn Ellis Building,
Maindy Road, Cardiff, CF24 4HQ, UK; E-mail: peallkj@cardiff.ac.uk
Marianne B. M. van den Bree and Kathryn J. Peall contributed equally
to this work.
Relevant conflicts of interest/financial disclosures: Drs Cunningham,
Fung, Massey, and Peall report no financial disclosures. Professors
Hall, Owen, and van den Bree are supported by a collaborative
research grant from Takeda Pharmaceutical Company Limited. Takeda
played no part in the conception, design, implementation, or interpreta-
tion of this study, and there is no benefit to them in relation to the
published work.
Funding agencies: This research was funded by the Medical Research
Council (MR/N022572/1 and MR/L011166/1), by the Baily Thomas Charita-
ble Trust (2315/1), the Waterloo Foundation (918-1234), the National Insti-
tute for Mental Health (5UO1MH101724), Wellcome Trust Strategic Award
(503147), Health & Care Research Wales (Welsh Government, 507556),
Medical Research Council Centre grant (G0801418), Medical Research
Council Programme grant (G0800509), and an Early Career Research Fel-
lowship from the Waterloo Foundation awarded to A.C.C. T.H.M. is funded
by an MRC Post-Doctoral Clinical Research Fellowship. K.J.P. is funded
by an MRC Clinician-Scientist Fellowship (MR/P008593/1).
Received: 6 February 2020; Revised: 27 March 2020; Accepted: 6 April
2020
Published online 00 Month 2020 in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/mds.28078
Movement Disorders, 2020 1
TABLE 1. Cohort demographic, motor, and nonmotor characteristics
22q11.2DS
Sibling
controls
22q11.2DS versus
sibling controls
22q11.2DS cohort: correlation analysis with
BFMDRS severity Scores
n (%)/mean
(SD)
n (%)/mean
(SD) P (95% CI) Correlation coefficient, r (P)
Total cohort (M : F) 19 (11:8) 13 (7:6) —
Age at examination (years), Median (range) 12.70
(6.8–17.1)
11.12
(7.5–17.5)
0.79 (−2.8 to 2.2) −0.24 (0.34)
FSIQ 78.83 (10.06) 109 (15.13) <0.0001 (21.16–39.64) −0.52 (0.03)
BFMDRS severity score (maximum possible
score, 120)
24.93 (8.17)
Medication
≥1 Medication prescribed 12 (63.2%) 0 (0%) 0.0004b
Melatonin 5 (26.3%) — —
Antibiotics 4 (21.1%) — —
Laxatives 3 (15.8%) — —
Vitamin/mineral supplementation 3 (15.8%) — —
Antidepressants 1 (5.3%) — —
Medical comorbidities
Cardiac defect 13 (68.4%) 0 (0%) 0.0001
ASD/VSD 5 (26.3%) — —
Tetralogy of Fallot 4 (21.1%) — —
Other 4 (21.1%) — —
Past/present seizures 1 (5.3%) 0 (0%) >0.99
Cleft lip/palate 6 (31.6%) 0 (0%) 0.06
Recurrent respiratory infections 7 (36.8%) 0 (0%) 0.02
Recurrent ear infections 6 (31.6%) 1 (7.7%) 0.20
Psychiatric symptoms
ADHD 7 (36.8%) 1 (7.7%) 0.10
Anxiety disorder (overall) 5 (26.3%) 1 (7.7%) 0.36
Social phobia 3 (15.8%) 0 (0%) 0.25
Generalized anxiety disorder 1 (5.3%) 0 (0%) >0.99
Specific phobia 1 (5.3%) 1 (7.7%) >0.99
ADHD count score 3.39 (3.38) 1.00 (3.16) 0.07 (−2,39 to 1.3) 0.41 (0.10)
Anxiety count score 2.13 (3.18) 1.75 (2.96) 0.78 (−3.17 to 2.42) 0.57 (0.03)
Autism trait symptoms score 11.43 (5.16) 2.50 (2.27) <0.0001
(−12.55 to −5.30)
0.42 (0.16)
Developmental history
Preterm birth 4 (21.1%) 5 (38.5%) 0.43
Failure to thrive 8 (42.1%) 0 (0%) 0.01
Feeding difficulties 16 (84.2%) 1 (7.7%) <0.0001
Parental reported clumsiness 15 (78.9%) 3 (23.1%) 0.003
Talking by 2 years of age 6 (31.6%) 12 (92.3%) 0.0009
Walking by 1.5 years of age 11 (57.9%) 11 (84.6%) 0.14
Statement of educational needs/education
and health care plan
13 (68.4%) 1 (7.7%) 0.0009
Age at riding a bike (years), median (range) 6.5 (5–10) 5 (3.5–7) 0.09 (−27.6 to 2.1) 0.02 (0.95)
Age at being able to button (years), median
(range)
6.2
(3.5–10.25)
4 (3–6.5) 0.008 (−41.6 to −7.0) −0.10 (0.79)
Age at being able to do laces (years),
median (range))
9.75 (6–11) 6.9 (5–8.7) 0.008 (−47.3 to 8.4) 0.20 (0.63)
Movement disorder
Evidence of movement disorder on
examination
18 (94.7%) 4 (30.8%) 0.0002
Dystonia 17 (94.4%) 3 (23.1%) 0.0002
Distal UL jerks (possible myoclonus/
possible chorea)
1 (5.6%) 1 (7.7%) >0.99
Body part affected
Eyes 0 (0%) 0 (0%) >0.99b
Oromandibular rgion 6 (31.6%) 0 (0%) 0.0 b
Cervical 8 (42.1%) 1 (7.7%) 0.05
Upper limbs 18 (94.7%) 4 (30.8%) 0.0002
Trunk 0 (0%) 0 (0%) >0.99
Lower limbs 8 (42.1%) 3 (23.1%) 0.45
(Continues)
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TABLE 1. Continued
22q11.2DS
Sibling
controls
22q11.2DS versus
sibling controls
22q11.2DS cohort: correlation analysis with
BFMDRS severity Scores
n (%)/mean
(SD)
n (%)/mean
(SD) P (95% CI) Correlation coefficient, r (P)
DCDQ scores
Overall 37.37 (12.54) 69.75 (6.90) <0.0001 (24.27–40.49) −0.29 (0.24)
Control during movement 15.21 (5.35) 28.17 (2.89) <0.0001 (9.51–16.4) −0.11 (0.65)
Fine motor score 10.95 (3.63) 19.33 (1.44) <0.0001 (6.13–10.64) −0.41 (0.09)
General coordination score 11.21 (5.34) 22.25 (3.98) <0.0001 (7.4–14.7) −0.29 (0.23)
ADHD, attention deficit hyperactivity disorder; DCDQ, Developmental Coordination Disorder Questionnaire; FSIQ, full-scale intelligence quotient; SCQ, Social
Communication Questionnaire; UL, upper limbs; Control during movement, fine motor score, and general coordination score all form subsections of the DCDQ.
The SCQ is used to measure Autism Trait Symptom Score, ADHD, and anxiety symptoms were measured using the Child and Adolescent Psychiatric Assessment
(CAPA).
Bold denotes P ≤ 0.05.
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